Longitudinal change in lung function and subsequent risks of cardiovascular events: evidence from four prospective cohort studies.
Cardiovascular events
Change
Coronary heart disease
Heart failure
Lung function
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
02 07 2021
02 07 2021
Historique:
received:
05
03
2021
accepted:
03
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Lung function is constantly changing over the life course. Although the relation of cross-sectional lung function measure and adverse outcomes has been reported, data on longitudinal change and subsequent cardiovascular (CV) events risks are scarce. Therefore, this study is to determine the association of longitudinal change in lung function and subsequent cardiovascular risks. This study analyzed the data from four prospective cohorts. Subjects with at least two lung function tests were included. We calculated the rate of forced respiratory volume in 1 s (FEV1) and forced vital capacity (FVC) decline for each subject and categorized them into quartiles. The primary outcome was CV events, defined as a composite of coronary heart disease (CHD), chronic heart failure (CHF), stroke, and any CV death. Cox proportional hazards regression and restricted cubic spline models were applied. The final sample comprised 12,899 participants (mean age 48.58 years; 43.61% male). Following an average of 14.79 (10.69) years, 3950 CV events occurred. Compared with the highest FEV1 quartile (Q4), the multivariable HRs for the lowest (Q1), 2nd (Q2), and 3rd quartiles (Q3) were 1.33 (95%CI 1.19, 1.49), 1.30 (1.16, 1.46), and 1.07 (0.95, 1.21), respectively. Likewise, compared with the reference quartile (Q4), the group that experienced a faster decline in FVC had higher HRs for CV events (1.06 [95%CI 0.94-1.20] for Q3, 1.15 [1.02-1.30] for Q2, and 1.28 [1.14-1.44] for Q1). The association remained robust across a series of sensitivity analyses and nearly all subgroups but was more evident in subjects < 60 years. We observed a monotonic increase in risks of CV events with a faster decline in FEV1 and FVC. These findings emphasize the value of periodic evaluation of lung function and open new opportunities for disease prevention.
Sections du résumé
BACKGROUND
Lung function is constantly changing over the life course. Although the relation of cross-sectional lung function measure and adverse outcomes has been reported, data on longitudinal change and subsequent cardiovascular (CV) events risks are scarce. Therefore, this study is to determine the association of longitudinal change in lung function and subsequent cardiovascular risks.
METHODS
This study analyzed the data from four prospective cohorts. Subjects with at least two lung function tests were included. We calculated the rate of forced respiratory volume in 1 s (FEV1) and forced vital capacity (FVC) decline for each subject and categorized them into quartiles. The primary outcome was CV events, defined as a composite of coronary heart disease (CHD), chronic heart failure (CHF), stroke, and any CV death. Cox proportional hazards regression and restricted cubic spline models were applied.
RESULTS
The final sample comprised 12,899 participants (mean age 48.58 years; 43.61% male). Following an average of 14.79 (10.69) years, 3950 CV events occurred. Compared with the highest FEV1 quartile (Q4), the multivariable HRs for the lowest (Q1), 2nd (Q2), and 3rd quartiles (Q3) were 1.33 (95%CI 1.19, 1.49), 1.30 (1.16, 1.46), and 1.07 (0.95, 1.21), respectively. Likewise, compared with the reference quartile (Q4), the group that experienced a faster decline in FVC had higher HRs for CV events (1.06 [95%CI 0.94-1.20] for Q3, 1.15 [1.02-1.30] for Q2, and 1.28 [1.14-1.44] for Q1). The association remained robust across a series of sensitivity analyses and nearly all subgroups but was more evident in subjects < 60 years.
CONCLUSIONS
We observed a monotonic increase in risks of CV events with a faster decline in FEV1 and FVC. These findings emphasize the value of periodic evaluation of lung function and open new opportunities for disease prevention.
Identifiants
pubmed: 34210292
doi: 10.1186/s12916-021-02023-3
pii: 10.1186/s12916-021-02023-3
pmc: PMC8252272
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153Références
Am J Epidemiol. 2003 Dec 15;158(12):1171-81
pubmed: 14652302
Ann Epidemiol. 1996 May;6(3):217-27
pubmed: 8827157
Circulation. 2014 Mar 4;129(9):971-80
pubmed: 24344084
Prog Clin Biol Res. 1984;147:501-21
pubmed: 6610878
J R Soc Med. 2015 Jan;108(1):32-7
pubmed: 25572993
Occup Environ Med. 1998 May;55(5):349-55
pubmed: 9764113
Thorax. 2006 Jun;61(6):472-7
pubmed: 16517577
Am J Respir Crit Care Med. 2016 Jul 1;194(1):3-5
pubmed: 27367881
Am J Respir Crit Care Med. 2006 May 1;173(9):985-90
pubmed: 16439715
Lancet Respir Med. 2019 Apr;7(4):358-364
pubmed: 30765254
Biopreserv Biobank. 2015 Aug;13(4):271-9
pubmed: 26186276
Eur J Heart Fail. 2012 Apr;14(4):348-50
pubmed: 22366235
Am J Respir Crit Care Med. 2009 Jul 1;180(1):3-10
pubmed: 19342411
Arch Intern Med. 2000 Jun 12;160(11):1683-9
pubmed: 10847262
Am J Kidney Dis. 2017 Nov;70(5):675-685
pubmed: 28754455
Eur Heart J. 2015 Jul 14;36(27):1754-61
pubmed: 25920404
Circulation. 2018 Apr 24;137(17):1814-1823
pubmed: 29352072
Thorax. 2015 May;70(5):482-9
pubmed: 25739910
J Am Coll Cardiol. 2018 Sep 4;72(10):1109-1122
pubmed: 30165982
Circulation. 2017 Jul 11;136(2):152-166
pubmed: 28696265
N Engl J Med. 1976 May 13;294(20):1071-5
pubmed: 1256523
Circulation. 2002 Nov 12;106(20):2555-60
pubmed: 12427651
Atherosclerosis. 2005 Jun;180(2):367-73
pubmed: 15910864
Eur J Heart Fail. 2012 Apr;14(4):414-22
pubmed: 22366234
Am Rev Respir Dis. 1986 Jan;133(1):14-20
pubmed: 3510578
Am J Respir Crit Care Med. 2020 Jul 15;202(2):210-218
pubmed: 32289231
Eur J Epidemiol. 2012 Dec;27(12):933-43
pubmed: 23238697
Br Med J. 1977 Jun 25;1(6077):1645-8
pubmed: 871704
BMJ. 1996 Sep 21;313(7059):711-5; discussion 715-6
pubmed: 8819439
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1385-1396
pubmed: 30433810
Lancet Glob Health. 2019 May;7(5):e613-e623
pubmed: 31000131
Am J Public Health. 1972 Nov;62(11):1506-11
pubmed: 5085517
Proc Am Thorac Soc. 2008 Dec 15;5(9):878-83
pubmed: 19056710
Eur J Neurol. 2011 Jun;18(6):888-98
pubmed: 21244584
PLoS One. 2017 Jun 14;12(6):e0178141
pubmed: 28614402
Ann Med. 2015;47(5):381-5
pubmed: 26153821
Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):390-8
pubmed: 7842197
Am J Med. 2011 Apr;124(4):334-41
pubmed: 21435424